Recross Cardio Inc.

About

Reducing the Risk of Stroke Through PFO Closure. Recross Cardio is a medical device company resolving patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke. We have initiated the U.S. FDA approved Early Feasibility Study (EFS), The PROTEA-PFO Study, to demonstrate the safety and efficacy of our P3 Occluder System.

Founders

• Thomas Gerhardt — Chief Executive Officer
• Gilberto Melnick — Co-Founder & Clinical Advisor

Investors

News

• Recross Cardio Announces First Patient Enrolled in PROTEA-PFO US-Early Feasibility Study · 2025-12-03T14:32:00.000Z
• Recross Cardio - 2026 Company Profile, Team & Competitors - Tracxn · 2026-06-14T00:00:00.000Z
• NCT07172464 - Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study | Syfrah · 2025-09-15T07:16:40.000Z
• Recross PFO Sealing System Early Feasibility Study Commences - Cardiac Interventions Today · 2025-12-08T16:43:07.000Z
• Recross Cardio - LIFTT · 2025-07-17T00:00:00.000Z
• Ten patients enrolled in the PROTEA-PFO Early Feasibility Study! This marks an important milestone for the study and reflects the strong commitment of our investigators, clinical sites, and centers… | Recross Cardio Inc. · 2026-06-02T15:48:16.000Z

Browse related software

• Clinic software in DE
• Clinic software in Dover
• All clinic software companies A–Z